Drugs Made In America Acquisition Corp., a blank check company focused on the pharmaceutical industry, has released its Form 10-Q report for the third quarter of 2025. The report provides a detailed overview of the company's financial performance and operational progress as it continues to seek a suitable business combination target.
Financial Highlights
Net Income: The company reported a net income of $2.18 million for the three months ended September 30, 2025, primarily driven by interest earned on cash and investments held in the trust account. For the nine months ended September 30, 2025, net income was $5.73 million, again largely due to interest income from the trust account.
Net Income Per Share: Basic and diluted net income per redeemable ordinary share was $0.07 for the three months ended September 30, 2025, and $0.19 for the nine months ended September 30, 2025. Similarly, basic and diluted net income per non-redeemable ordinary share was $0.07 for the three months ended September 30, 2025, and $0.19 for the nine months ended September 30, 2025.
Business Highlights
Business Model and Purpose: Drugs Made In America Acquisition Corp. is a blank check company incorporated in the Cayman Islands, focused on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, primarily in the pharmaceutical industry.
IPO and Fundraising: The company successfully completed its Initial Public Offering (IPO) on January 29, 2025, raising $200 million through the sale of 20 million units at $10.00 per unit. An additional $30 million was raised through the exercise of the over-allotment option by underwriters, bringing the total funds raised to $230 million.
Trust Account and Investment Strategy: Following the IPO, $231.15 million was placed in a trust account, which is invested in U.S. government treasury obligations or money market funds. The funds are intended to be used for the completion of a business combination.
Operational Focus: The company is in the early stages of identifying a target for a business combination and has not yet commenced any operations. The focus remains on the pharmaceutical industry, leveraging the funds raised to identify and acquire a suitable target.
Management and Administrative Support: The company has an administrative services agreement with its sponsor, Drugs Made In America Acquisition LLC, to provide office space and administrative support for $10,000 per month.
Future Outlook and Business Combination Timeline: The company has a 15-month window from the IPO closing date (April 29, 2026) to complete a business combination, with the possibility of extending this period by up to six additional months, subject to certain conditions.
Risk Factors and Market Conditions: The company acknowledges the geopolitical instability and market volatility due to the Russia-Ukraine conflict and the Israel-Hamas conflict, which could impact its ability to successfully complete a business combination.
Segment Information: The company operates as a single segment, with the Chief Executive Officer acting as the Chief Operating Decision Maker, focusing on net income or loss as the primary measure of performance.
SEC Filing: